Rheumatoid Arthritis
Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an impact on our practice? Here is my selection of 3 abstracts presented at EULAR 2026 that identify therapeutic strategies that are well worth keeping on our radar.
Nelly ZIADE 🍀 Nellziade
2 months ago
@RheumNow HOT #Obesity session (7)
📢A call for action
Current RMD treatments ignore obesity:
They all target immune response but miss the metabolic-inflammatory loop
Breaking that cycle may be the missing piece
Obesity must be part of every rheumatology plan
#EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade
2 months ago
☂️What is an umbrella meta-analysis?
It's a meta-analysis of meta-analyses ☔️
⬇️This one showed the effect of diet supplementation on several RA outcomes
Unfortunately, most studies have low levels of evidence
#umbrella #rainy_London #EULAR2026 @rheumnow https://t.co/kYPchXEexn
Janet Pope Janetbirdope
2 months ago
DR JOHN STONE gives Overview
Of
#IgG4
New non B cell depleter
#obexelimab N=194 in RCT
To add to B cell depletion w
#Inebilizumab
Off label but used also
#Rituximab
#steroids
#Immunesuppressives
Other investigational drugs
Ex #JAKi
#EULAR2026 @RheumNow
#OP018 #RULARbest https://t.co/Y4saGYcdww
Nelly ZIADE 🍀 Nellziade
2 months ago
🧬 Does spine vs knee enthesis differ immunologically?
Translational scRNAseq study: YES!
Spine produces more IL-23 but shows attenuated IL-17 response vs knee
#POS0084 #EULAR2026 @RheumNow https://t.co/itFrLEXSzZ
Mrinalini Dey DrMiniDey
2 months ago
Who should we screen for RA-ILD?
RA-ILD remains a serious extra-articular manifestation, contributing to morbidity and mortality.
At #EULAR2026, two abstracts shed light on clinical phenotyping and risk profiling.
Read my report for @RheumNow:
https://t.co/CTtYHINXxU
Janet Pope Janetbirdope
2 months ago
Good news! #Survival in #SLE is improving
#SLR of #lupus publications over time in 233 publications
Bad news - still a mortality gap!
#EULAR2026
@RheumNow @eular_org
ABST#POS0684 https://t.co/PVmQI2duYS
Nelly ZIADE 🍀 Nellziade
2 months ago
❤️ Do biologics differ in MACE risk in PsA?
YES - JAKi highest risk after 2.5yrs vs TNFi/IL-17i/IL-23i in a retrospective cohort of 22,246pts.
OP0181 #EULAR2026 @RheumNow https://t.co/eQdBtMfRAY
Antoni Chan MD (Prof) synovialjoints
2 months ago
Male sex independently associated with greater mSASSS increase (β 0.29), higher odds of ≥2-unit mSASSS progression (OR 2.08), and new syndesmophyte formation (OR 1.90) in #axSpA despite lower disease activity scores. Treat symptoms and progression Abstr OP0101 @RheumNow
Jiha Lee JihaRheum
2 months ago
RD in #IBD: 18.6% of 650 IBD pts affected, most commonly peripheral arthritis and AxSpa. Key finding: 14% of rheumatic manifestations preceded IBD diagnosis. Rheumatologists may see these pts first. GI-rheum collaboration is essential. @RheumNow #EULAR2026 POS0807 https://t.co/028yzOxJ2R
Antoni Chan MD (Prof) synovialjoints
2 months ago
Over 10 years in the GESPIC cohort, males with #axSpA had lower ASDAS/BASDAI and enthesitis but double the odds of significant spinal radiographic progression vs females (OR 2.08). Symptoms don’t always correlate to structural damage Abstr OP0101 @RheumNow #EULAR2026
Jiha Lee JihaRheum
2 months ago
After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival at 12m) and axSpA (80% vs 68%), but not RA. Yet 74% of axSpA pts still got another TNFi. Evidence vs practice gap in plain sight. @RheumNow #EULAR2026 POS0776
Jiha Lee JihaRheum
2 months ago
JAKi vs ABA in RA-ILD: emulated target trial (n=1,162), JAKi with worse composite respiratory outcomes (HR 1.57) and all-cause mortality (HR 1.59) vs ABA over 5 yrs. JAKi with ↑ pneumonia risk. In RA-ILD, ABA may be the preferred choice? @RheumNow #EULAR2026 POS0813 #EULARBEST
Nelly ZIADE 🍀 Nellziade
2 months ago
@RheumNow WIN Nutrition session #EULAR2026 (4)
🌾 Gluten does NOT influence biologic response in RD, BELIEVE cohort, 197 pts. No need to go gluten-free unless celiac disease
🌱 Plants for Joints trial: plant-based diet + exercise → sustained DAS28&WOMAC improvement @ 2Y, RA/OA
@RheumNow
